CAVE CREEK, AZ--(Marketwired - Sep 7, 2016) - Endexx Corporation (OTC PINK: EDXC), a provider of innovative phyto-nutrient based food and nutritional products, is excited to announce the launch of its new pet product line, Phyto-Bites®, its CBD-infused soft chews for dogs. The dog treats are formulated to promote health and support the reduction of separation anxiety, pain and inflammation.
Phyto-Bites® soft chews were developed according to a proprietary formula and are manufactured under cGMP in a FDA approved facility by Precision Science, a global contract manufacturer of animal pharmaceuticals, nutraceuticals and medicated feed products. (http://precisionscience.com).
Phyto-Bites® are nutritious and support overall dog health. The soft chews are available in packages of 30 and 60 chews and have a two-year shelf life. The soft chews were tested on a variety of dogs that exhibited reduced symptoms of separation anxiety.
According to the American Pet Products association, dog owners in the US will spend an estimated $48 billion in 2016, of which $12.5 billion will be spent on veterinary care. The market potential for CBD infused dog products cannot be understated. Endexx is leading a far-reaching marketing campaign through its broker network and is positioned to enter the major pet food retailers during the next fiscal year beginning in October.
Todd Davis, CEO of Endexx, stated, "Our mission is to create innovative and healthy products that improve the overall lifestyle and quality of life and that extends to our pet companions as well. Given the huge market opportunity, we believe this product will address a multi-billion industry for dog wellness."
Endexx provides innovative medical marijuana management and technology solutions. Endexx, with its collaborative partners and consultants, develops and distributes two consumable product lines derived from industrial hemp, which is organic and naturally rich in phytocannabinoids. The company has two technology products and services that launched in 2014 -- the M3hub and the Autospense™. Both products provide essential solutions to promote regulatory compliance and full accountability through "seed to sale" inventory management and tracking. Based on principles developed by the pharmacological industry, the m3hub platform is the first standardized software solution for tracking pharmaceutical grade marijuana that maintains compliance with federal, state and local regulations. It is intended to provide a smooth transition to an eventual federal mandates. The Autospense™ is a high-tech marijuana inventory control and dispensing device that provides up-to-the-minute accounting details and ensures both product and patient security. By automating the dispensing process, Autospense™ increases productivity and reduces costs for marijuana retailer, while enhancing their service quality by reducing transaction time for customers. Websites include: www.cbdunlimited.com, www.endexx.com, and www.m3hub.com.
Safe Harbor Notice
This press release may contain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995, such as statements relating to financial results and plans for future development activities, and are thus prospective. Forward-looking statements include all statements that are not statements of historical fact regarding intent, belief or current expectations of the Company, its directors or its officers. Investors are cautioned that any such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, many of which are beyond the Company's ability to control. Actual results may differ materially from those projected in the forward-looking statements. Among the factors that could cause actual results to differ materially from those indicated in the forward-looking statements are risks and uncertainties associated with the Company's business and finances in general, including the ability to continue and manage its growth, competition, global economic conditions and other factors discussed in detail in the Company's periodic filings with the Security and Exchange Commission. The Company undertakes no obligation to update any forward-looking statements.